At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,053 enrolled
Drug / intervention
Technosphere® Insulin Inhalation Powder +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pulmonary Outcomes Within a 2-Year Period in Subjects With Diabetes Mellitus Treated With Technosphere /Insulin or Usual Antidiabetic Treatment and in Subjects Without Abnormalities in Glucose Control.
In Brief
A Phase 3 clinical trial evaluating Technosphere® Insulin Inhalation Powder and Usual Care for Diabetes, Type 1 and Diabetes, Type 2. Completed, enrolled 2,053 participants across 176 sites in 8 countries.
Detailed Summary
Pulmonary Safety in Diabetics with T/I
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Type 1, Diabetes, Type 2
CountriesCanada, Czechia, Poland, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedMar 2006
Primary CompletionSep 2008
Study CompletionOct 2008
TodayJul 2026
First PostedMar 30, 2006
Enrollment StartJun 1, 2005
Primary CompletionSep 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.3 years ago
Interventions
Technosphere® Insulin Inhalation Powderdrug
Inhalation, 15U/30U
Usual Caredrug
Subjects will receive antidiabetes treatment at the discretion of their physicians